AXGN Stock Forecast 2025-2026
Distance to AXGN Price Targets
AXGN Price Momentum
10 Quality Stocks Worth Considering Now
Researching AxoGen (AXGN) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on AXGN and similar high-potential opportunities.
Latest AXGN Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, AXGN has a bullish consensus with a median price target of $25.00 (ranging from $24.00 to $26.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $17.25, the median forecast implies a 44.9% upside. This outlook is supported by 6 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from David Turkaly at Citizens Capital Markets, projecting a 50.7% upside. Conversely, the most conservative target is provided by Ross Osborn at Cantor Fitzgerald, suggesting a 39.1% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
AXGN Analyst Ratings
AXGN Price Target Range
Latest AXGN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for AXGN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 5, 2025 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $24.00 |
| Mar 5, 2025 | Citizens Capital Markets | David Turkaly | Market Outperform | Reiterates | $26.00 |
| Feb 26, 2025 | Citizens Capital Markets | Constantine Davides | Market Outperform | Maintains | $26.00 |
| Feb 26, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $26.00 |
| Feb 3, 2025 | Canaccord Genuity | Caitlin Cronin | Buy | Maintains | $22.00 |
| Aug 9, 2024 | JMP Securities | David Turkaly | Market Outperform | Maintains | $20.00 |
| Jul 1, 2024 | Raymond James | Jayson Bedford | Outperform | Initiates | $13.00 |
| Jun 20, 2024 | Canaccord Genuity | Caitlin Cronin | Buy | Reiterates | $15.00 |
| Jan 19, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $12.00 |
| Dec 7, 2023 | Canaccord Genuity | Caitlin Cronin | Buy | Reiterates | $11.00 |
| Oct 16, 2023 | Leerink Partners | Mike Kratky | Outperform | Initiates | $9.00 |
| Sep 26, 2023 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $16.00 |
| Aug 22, 2023 | Cantor Fitzgerald | Travis Steed | Overweight | Reiterates | $16.00 |
| May 10, 2023 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $20.00 |
| Mar 28, 2023 | Canaccord Genuity | Kyle Rose | Buy | Reiterates | $15.00 |
| Mar 15, 2023 | JMP Securities | David Turkaly | Market Outperform | Reiterates | $20.00 |
| Nov 11, 2022 | Jefferies | Michael Sarcone | Buy | Assumes | $15.00 |
| May 9, 2022 | Canaccord Genuity | Kyle Rose | Buy | Upgrade | $15.00 |
| May 5, 2022 | SVB Leerink | Danielle Antalffy | Outperform | Maintains | $14.00 |
| Nov 4, 2021 | JMP Securities | Market Outperform | Maintains | $20.00 |
Axogen Inc. (AXGN) Competitors
The following stocks are similar to AxoGen based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Axogen Inc. (AXGN) Financial Data
Axogen Inc. has a market capitalization of $764.93M with a P/E ratio of 0.0x. The company generates $187.34M in trailing twelve-month revenue with a -5.3% profit margin.
Revenue growth is +15.1% quarter-over-quarter, while maintaining an operating margin of +4.1% and return on equity of -10.0%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Axogen Inc. (AXGN) Business Model
About Axogen Inc.
Develops solutions for peripheral nerve injuries.
Axogen Inc. generates revenue by developing and commercializing medical devices specifically designed for peripheral nerve repair. Its products, which include nerve grafts, connectors, and protectors, are sold to hospitals and surgical centers, primarily used in reconstructive surgeries to enhance patient recovery outcomes.
Headquartered in Alachua, Florida, Axogen is actively involved in research and development to innovate and improve nerve repair technologies, positioning itself as a key player in the surgical and orthopedic markets. The company aims to meet unmet medical needs and redefine standards in nerve repair procedures.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
451
CEO
Ms. Karen Zaderej
Country
United States
IPO Year
1990
Website
www.axogeninc.comAxogen Inc. (AXGN) Latest News & Analysis
Axogen, Inc. (NASDAQ:AXGN) will host its Q4 2024 earnings call on February 25, 2025, at 8:00 AM ET, featuring executives including CEO Michael Dale and CFO Nir Naor.
The Q4 earnings call provides insights into Axogen's financial performance and strategic direction, influencing investor sentiment and stock price movements.
Axogen, Inc. (NASDAQ: AXGN) will host its Analyst & Investor Day on March 4, 2025, from 9am to 12pm ET, focusing on surgical solutions for peripheral nerve injuries.
Axogen's Analyst & Investor Day could reveal strategic insights and future growth plans, influencing stock performance and investor sentiment in the nerve repair market.
Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
1 month agoAxogen, Inc. will report its Q4 and full-year 2024 financial results on February 25, 2025, before market opens, followed by a conference call at 8 a.m. ET.
Axogen's upcoming financial results announcement may impact stock performance, providing insights into revenue trends and business growth, crucial for assessing investment potential.
AxoGen (AXGN) shares rose with above-average trading volume, but recent earnings estimate revisions may not lead to immediate price increases.
AxoGen's share surge indicates heightened investor interest, but the caution on earnings revisions suggests potential volatility and uncertainty ahead, impacting short-term investment strategies.
AxoGen (AXGN) has reached a 52-week high. Investors are encouraged to examine the company's fundamentals for insights on potential future gains.
AxoGen's 52-week high signals strong market performance. Analyzing its fundamentals can indicate potential for continued growth or risks, influencing investment decisions.
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2 months agoCraig Swandal has joined the leadership team of a medical device manufacturing company, bringing his extensive experience to the role.
Craig Swandal's appointment enhances leadership credibility and expertise in the medical device sector, potentially driving innovation and growth, which can positively impact stock performance.
Frequently Asked Questions About AXGN Stock
What is Axogen Inc.'s (AXGN) stock forecast for 2025?
Based on our analysis of 12 Wall Street analysts, Axogen Inc. (AXGN) has a median price target of $25.00. The highest price target is $26.00 and the lowest is $24.00.
Is AXGN stock a good investment in 2025?
According to current analyst ratings, AXGN has 6 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $17.25. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for AXGN stock?
Wall Street analysts predict AXGN stock could reach $25.00 in the next 12 months. This represents a 44.9% increase from the current price of $17.25. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Axogen Inc.'s business model?
Axogen Inc. generates revenue by developing and commercializing medical devices specifically designed for peripheral nerve repair. Its products, which include nerve grafts, connectors, and protectors, are sold to hospitals and surgical centers, primarily used in reconstructive surgeries to enhance patient recovery outcomes.
What is the highest forecasted price for AXGN Axogen Inc.?
The highest price target for AXGN is $26.00 from David Turkaly at Citizens Capital Markets, which represents a 50.7% increase from the current price of $17.25.
What is the lowest forecasted price for AXGN Axogen Inc.?
The lowest price target for AXGN is $24.00 from Ross Osborn at Cantor Fitzgerald, which represents a 39.1% increase from the current price of $17.25.
What is the overall AXGN consensus from analysts for Axogen Inc.?
The overall analyst consensus for AXGN is bullish. Out of 12 Wall Street analysts, 6 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $25.00.
How accurate are AXGN stock price projections?
Stock price projections, including those for Axogen Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
